You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

278 Results
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
This is FR page
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
ODB - General Benefit
    filgrastim (biosimilars) - refer to ODB Formulary for details
Nov 2025
Document
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Oct 2024
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Drug
Other Name(s): Opdualag™
Feb 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
May 2025
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
May 2025
Drug
Other Name(s): Akeega™
Sep 2025
Les fiches d’information sur les soins palliatifs pour les Autochtones sont élaborées afin de soutenir les membres des Premières Nations, des Inuits...

Pages